Zieger K - Search Results

1

Consultation on UTUC II Stockholm 2022: diagnostic and prognostic methods-what's around the corner?

Grahn A, Coleman JA, Eriksson Y, Gabrielsson S, Madsen JS, Tham E, Thomas K, Turney B, Uhlén P, Vollmer T, Zieger K, Osther PJS, Brehmer M. Grahn A, et al. Among authors: zieger k. World J Urol. 2023 Dec;41(12):3405-3411. doi: 10.1007/s00345-023-04597-4. Epub 2023 Sep 19. World J Urol. 2023. PMID: 37725130 Free PMC article. Review.

2

The diagnostic challenge of suspicious or positive malignant urine cytology findings when cystoscopy findings are normal: an outpatient blue-light flexible cystoscopy may solve the problem.

Andersson M, Berger M, Zieger K, Malmström PU, Bläckberg M. Andersson M, et al. Among authors: zieger k. Scand J Urol. 2021 Aug;55(4):263-267. doi: 10.1080/21681805.2021.1928746. Epub 2021 May 26. Scand J Urol. 2021. PMID: 34037496

3

Long-term survival of patients with bladder tumours: the significance of risk factors.

Zieger K, Wolf H, Olsen PR, Højgaard K. Zieger K, et al. Br J Urol. 1998 Nov;82(5):667-72. doi: 10.1046/j.1464-410x.1998.00848.x. Br J Urol. 1998. PMID: 9839581

4

Long term follow-up of superficial invasive bladder carcinoma with or without concomitant epithelial atypia--recurrence and progression.

Zieger K, Olsen PR, Wolf H, Højgaard K. Zieger K, et al. Scand J Urol Nephrol. 2002 Feb;36(1):52-9. doi: 10.1080/003655902317259373. Scand J Urol Nephrol. 2002. PMID: 12002359

5

Recent developments in molecular profiling of bladder cancer.

Ørntoft TF, Zieger K, Dyrskjøt L. Ørntoft TF, et al. Among authors: zieger k. Curr Opin Urol. 2006 Sep;16(5):377-81. doi: 10.1097/01.mou.0000240313.16324.d3. Curr Opin Urol. 2006. PMID: 16905986 Review.

6

Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.

Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbayo M, Segersten U, Malmström PU, Hartmann A, Palou J, Alvarez-Múgica M, Zieger K, Borre M, Ørntoft TF, Dyrskjøt L. Fristrup N, et al. Among authors: zieger k. Am J Pathol. 2012 May;180(5):1824-34. doi: 10.1016/j.ajpath.2012.01.023. Epub 2012 Mar 24. Am J Pathol. 2012. PMID: 22449953

7

Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis.

Lykke MR, Nielsen TK, Ebbensgaard NA, Zieger K. Lykke MR, et al. Among authors: zieger k. Scand J Urol. 2015 Jun;49(3):230-6. doi: 10.3109/21681805.2015.1019562. Epub 2015 Mar 2. Scand J Urol. 2015. PMID: 25731785

8

A molecular signature in superficial bladder carcinoma predicts clinical outcome.

Dyrskjøt L, Zieger K, Kruhøffer M, Thykjaer T, Jensen JL, Primdahl H, Aziz N, Marcussen N, Møller K, Orntoft TF. Dyrskjøt L, et al. Among authors: zieger k. Clin Cancer Res. 2005 Jun 1;11(11):4029-36. doi: 10.1158/1078-0432.CCR-04-2095. Clin Cancer Res. 2005. PMID: 15930337

9

Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.

Zieger K, Jensen KM. Zieger K, et al. Scand J Urol Nephrol. 2011 Dec;45(6):411-8. doi: 10.3109/00365599.2011.599335. Epub 2011 Jul 27. Scand J Urol Nephrol. 2011. PMID: 21793636

10

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

Zieger K, Dyrskjøt L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Ørntoft TF. Zieger K, et al. Clin Cancer Res. 2005 Nov 1;11(21):7709-19. doi: 10.1158/1078-0432.CCR-05-1130. Clin Cancer Res. 2005. PMID: 16278391

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page